 | Up a level |
Gautschi, O.; Mach, N.; Rothschild, S.; Li, Qiyu; Stahel, R. A.; Zippelius, A.; Cathomas, R.; Früh, M.; Betticher, D. C.; Peters, S.; Rauch, D.; Feilchenfeldt, J.; Bubendorf, L.; Savic, S.; Jaggi, Rolf; Oppliger Leibundgut, Elisabeth; Largiadèr, Carlo Rodolfo; Brutsche, M.; Pilop, C.; Stalder, L.; ... (2015). Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clinical lung cancer, 16(5), pp. 358-365. Elsevier 10.1016/j.cllc.2015.02.007
Jermann, M.; Jost, L. M.; Taverna, Ch.; Jacky, E.; Honegger, H. P.; Betticher, D. C.; Egli, F.; Kroner, Th.; Stahel, R. A. (2004). Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Annals of oncology, 15(3), pp. 511-516. Oxford University Press 10.1093/annonc/mdh093
Gautschi, Oliver; Zangemeister-Wittke, U.; Stahel, R. A. (2003). Comment on “A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer”, by C. M. Rudin et al. (Ann Oncol 2002; 13: 539–545). Annals of oncology, 14(1), p. 170. Oxford University Press 10.1093/annonc/mdg001
